国泰海通证券 | 研究所 2025上海先导产业7 暨第14届医药CEO论坛 +第5届人工智能大会 2025年9月4日-5日 | 上海浦东文华东方酒店 家和豆 外科技 官席分 未文心 郎所长、科技组 物医药直席分 9月4日-5日全天小时日本 * 拟邀请上市公司(持续更新中),排名不分先后 更新时间: 2025/8/18/09:30 | 制药 | | | | | | | --- | --- | --- | --- | --- | --- | | 艾力斯 | 歌礼制药 | 君实生物 | 册珠集团 | 只新约业 | 益方生物 | | 白利天恒 | 翰森制药 | 凯因科技 | 联邦制药 | 信达生物 | 映恩生物 | | 贝达药业 | 和誉 | 康方生物 | 绿叶制药 | 信立泰 | 悦康药业 | | 博瑞医药 | 恒瑞医药 | 康弘药业 | 荣昌生物 | 亚盛医药 | 电鼎医药 | | 德琪医药 | 华东医药 | 科伦博泰 | 三生国健 | 药捷安康 | 泽璟制药 | | 图华药业 | 北京的药 | 科伦药业 | 三生制药 | 宜明昂科 | 众生药业 | | 复宏汉霖 | 汇宇制药 | 来凯医药 | 微芯生物 | 中 ...

智通财经APP获悉，中信建投发布研报称，中国医药产业具备人口与内需优势、制造与供应链优势，同 时创新能力快速提升，中国资产出海数量也持续提升。在复杂的外部挑战下，中国医药行业需"立足于 内，开拓于外"，对内坚持供应链自主可控，拥抱创新和整合；对外加速国际化布局，捕捉全球医药产 业链变革机遇。展望2025年下半年，继续看好新增量（创新、出海、边际变化）和行业整合机会。 中信建投主要观点如下： 全球视角：外部挑战加剧，中国医药产业竞争力持续提升 从国际比较优势看，中国具备人口与内需优势、制造与供应链优势，同时创新能力快速提升，中国资产 出海数量也持续提升。美国在创新与早期研发方面优势明显，同时具有高定价的内需市场。虽然外部挑 战加大，但海外市场仍有很大机会，建议同时关注国内份额提升及出海的机会。 立足于内：稳住国内根基，拥抱创新与整合 ①政策展望：改革进入深水区，高质量增长成为常态。2025年下半年该行重点关注的是药品和耗材集采 政策优化、多元化支付及医疗服务价格改革。②制药产业链：集采优化、积极创新转型，关注供应链安 全。③器械：看好进口替代和并购整合机会，积极关注AI和脑机接口等新技术方向。④关注中药、药 店 ...

Core Insights - The uncertainty surrounding U.S. tariffs on pharmaceuticals is impacting the global pharmaceutical sector, but the overall effect on China's pharmaceutical industry is expected to be limited [1][2] - Chinese CXO (Contract Research Organization) companies are becoming increasingly significant in the global supply chain, but the impact of tariffs will primarily be felt by their clients, leading to increased supply costs [2] - The rise of innovative drugs in China is notable, particularly in the Hong Kong market, where clinical-stage products are being evaluated based on their potential global market performance [2][3] Impact of Tariffs - The potential tariffs are likely to have a limited impact on China's pharmaceutical industry, especially for finished drugs, as the export volume is relatively small [1] - For medical device companies, the exposure to the U.S. market is also limited, with many products targeting emerging markets instead [1] - Companies with exposure to the U.S. market may prioritize depleting their existing inventory in the U.S. in response to tariff uncertainties [1] CXO Industry Dynamics - Most tariff costs will be borne by clients of CXO companies, which may lead to increased supply chain costs [2] - The process of reshoring manufacturing to the U.S. is complex and time-consuming, requiring 2-3 years for new facilities and additional time for regulatory approvals [2] - The talent pool necessary for replicating China's CDMO success is difficult to establish in the U.S. and Europe, making it challenging to recreate the same level of global influence [2] Innovative Drug Market - The evaluation of clinical-stage products is based on their projected peak sales and market penetration, which has become more familiar to investors since the opening of the Hong Kong market to unprofitable biotech firms [2] - Chinese innovative drugs are gaining global recognition, leading to increased investor interest as companies begin to license products internationally [2][3] - The competitive landscape for Chinese innovative drugs is still developing, with further observation needed over the next 3-5 years to assess their commercial viability against global competitors [3][4] Future Disease Areas - Oncology remains a significant area of exploration, with continued opportunities for growth [4] - Other promising fields include autoimmune diseases, metabolic disorders, and neurodegenerative diseases [4]

Group 1 - The Hong Kong stock market opened lower on May 19, with the Hang Seng Index down 0.73% and the Hang Seng Tech Index down 1.58% [1] - The Hong Kong Innovative Drug ETF (159567) rose by 0.58% with a turnover rate of 8.02% and a trading volume exceeding 1.15 billion yuan, indicating active trading [1] - The innovative drug ETF closely tracks the Hong Kong Stock Connect Innovative Drug Index, reflecting the performance characteristics of biotech companies listed in Hong Kong [1] Group 2 - The pharmaceutical sector has shown a strong rebound this year, with several pharmaceutical funds reporting net value increases exceeding 30% [1] - Institutions are focusing on investment opportunities in AI healthcare, brain-computer interfaces, and innovative drugs following a period of deep adjustment in the pharmaceutical sector [1] - Guojin Securities emphasizes that innovative drugs and certain semi-innovative drugs remain key investment areas, with upcoming policy changes and data releases expected to catalyze stock price movements [1] Group 3 - Guoxin Securities highlights the rapid growth phase of the innovative drug sector, driven by commercialization and external licensing, which is accelerating revenue growth and profitability [2] - The traditional Chinese medicine sector faces short-term pressure but retains long-term branding and innovation potential [2] - The medical device sector is under short-term pressure due to slow policy implementation and inventory issues, but there are expectations for recovery driven by improved bidding processes [2]

Core Viewpoint - The Chinese pharmaceutical industry needs to "focus on domestic stability while expanding internationally" in the context of a reshaped global landscape, promoting technological self-sufficiency and accelerating internationalization to address tariff policies and geopolitical challenges, while seizing opportunities from global pharmaceutical industry chain transformations [1] Summary by Relevant Categories Industry Outlook - The industry is expected to benefit from the trend of self-sufficiency and the export of medical devices, with a long-term positive outlook [1] - There is an emphasis on stabilizing domestic foundations while actively participating in industry consolidation and exploring overseas markets [1] Tariff and Geopolitical Impact - The recent U.S. tariff increases on China included a temporary exemption for pharmaceuticals, indicating limited impact on the sector [1] - The primary method for innovative drug companies to expand internationally is through intellectual property (IP) transfer, which also has a limited effect [1]